GALT Galectin Therapeutics Inc.: Enterprise Value-to-Revenue Ratio

Official company branding of Galectin Therapeutics, Inc. (GALT)

Galectin Therapeutics focuses on combating fibrosis through its drug Belapectin, although global conflicts could slow down international trials. The EV to total revenue multiple reflects the business valuation trend, where the current parameter equals 0.00. Meanwhile, drug development within the secure US system minimizes geopolitical risks, ensuring the stability of research.

Galectin Therapeutics Inc. (GALT): EV/Sales Multiple from 11/23/2025 to 11/20/2026

Galectin Therapeutics, Inc. - analytical breakdowns and key metrics (GALT)

- current quotes and average value forecast:
- company stock capitalization data:
Initial company analysis:Galectin Therapeutics, GALT
Manufactured products of Galectin Therapeutics Inc.

The fundamental attractiveness of Galectin Therapeutics (GALT) is determined by comparing the business's market value with its operating income. The EV-to-annual revenue multiple measures the total enterprise value, including debt, relative to sales volume. An increase in this indicator above market norms signals an overvaluation of the asset. For Galectin Therapeutics, current levels reflect the anticipation of Phase 3 trial data, as the market has already priced in the extended testing period.